Increased ERK activation and cellular drug accumulation in the enhanced cytotoxicity of folate receptor-targeted liposomal carboplatin

International Journal of Oncology

Volumn 40, Issue 3, 2012, Pages 703-710

  Chaudhury, Anumita ^a   Tan, Bee Jee ^a   Das, Surajit ^a   Chiu, Gigi N C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Carboplatin; ERK activation; Folate receptor; Liposomes; Targeted delivery

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CARBOPLATIN; FOLATE RECEPTOR; FOLIC ACID; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE; UO 126;

ARTICLE; CANCER CELL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIZATION; DRUG UPTAKE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FOLATE RECEPTORS, GPI-ANCHORED; HUMANS; KB CELLS; LIPOSOMES; PHOSPHORYLATION;

EID: 84863393746     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1262     Document Type: Article

References (40)

1. Sorenson CM, Barry MA and Eastman A: Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82: 749-755, 1990. (Pubitemid 20159274)
2. Eastman A: Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). Biochemistry 22: 3927-3933, 1983.
3. Harrap KR: Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 12 (Suppl): A21-A33, 1985.
4. Calvert AH, Harland SJ, Newell DR, et al: Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9: 140-147, 1982. (Pubitemid 13253279)
5. Curt GA, Grygiel JJ, Corden BJ, et al: A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240). Cancer Res 43: 4470-4473, 1983. (Pubitemid 13041890)
6. Rajeswaran A, Trojan A, Burnand B, et al: Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59: 1-11, 2008.
7. Torchilin VP: Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4: 145-160, 2005.
8. Chiu GN, Wong MY, Ling LU, et al: Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: Implications on pharmacokinetics and drug toxicities. Curr Drug Metab 10: 861-874, 2009.
9. Immordino ML, Dosio F and Cattel L: Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 1: 297-315, 2006.
10. Bandak S, Goren D, Horowitz A, et al: Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs 10: 911-920, 1999. (Pubitemid 30061363)
11. Newman MS, Colbern GT, Working PK, et al: Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43: 1-7, 1999. (Pubitemid 29048341)
12. Medina OP, Zhu Y and Kairemo K: Targeted liposomal drug delivery in cancer. Curr Pharm Des 10: 2981-2989, 2004. (Pubitemid 39214006)
13. Kaneda Y: Virosomes: evolution of the liposome as a targeted drug delivery system. Adv Drug Deliv Rev 43: 197-205, 2000.
14. Allen TM: Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2: 750-763, 2002.
15. Torchilin V: Antibody-modified liposomes for cancer chemotherapy. Expert Opin Drug Deliv 5: 1003-1025, 2008.
16. Sudimack J and Lee RJ: Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41: 147-162, 2000. (Pubitemid 30122955)
17. Pan X and Lee RJ: Tumour-selective drug delivery via folate receptor-targeted liposomes. Expert Opin Drug Del 1: 7-17, 2004. (Pubitemid 40297953)
18. Zhao X, Li H and Lee RJ: Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 5: 309-319, 2008. (Pubitemid 351454380)
19. Kelemen LE: The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 119: 243-250, 2006.
20. Spannuth WA, Sood AK and Coleman RL: Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 10: 431-437, 2010.
21. Konner JA, Bell-McGuinn KM, Sabbatini P, et al: Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 16: 5288-5295, 2010.
22. Stephenson SM, Low PS and Lee RJ: Folate receptor-mediated targeting of liposomal drugs to cancer cells. Methods Enzymol 387: 33-50, 2004.
23. Mayer LD, Bally MB, Hope MJ, et al: Techniques for encapsulating bioactive agents into liposomes. Chem Phys Lipids 40: 333-345, 1986. (Pubitemid 16040787)
24. Woo J, Chiu GN, Karlsson G, et al: Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm 349: 38-46, 2008.
25. Fiske CH and Subbarow Y: The colorimetric determination of phosphorus. J Biol Chem 66: 375-400, 1925.
26. Meyer AH: Development of a permanent blue color for colorimetric phosphorus determination. Science 72: 174, 1930.
27. Meerum Terwogt JM, Tibben MM, Welbank H, et al: Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 366: 298-302, 2000.
28. Bose RN: Biomolecular targets for platinum antitumor drugs. Mini Rev Med Chem 2: 103-111, 2002.
29. Wang X, Martindale JL and Holbrook NJ: Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275: 39435-39443, 2000. (Pubitemid 32058968)
30. Park SA, Park HJ, Lee BI, et al: Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Brain Res Mol Brain Res 93: 18-26, 2001. (Pubitemid 32786898)
31. Woessmann W, Chen X and Borkhardt A: Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother Pharmacol 50: 397-404, 2002. (Pubitemid 35446295)
32. Fung MK, Cheung HW, Ling MT, et al: Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells. Br J Cancer 95: 475-484, 2006. (Pubitemid 44232557)
33. Upadhyay AK, Ajay AK, Singh S, et al: Cell cycle regulatory protein 5 (Cdk5) is a novel downstream target of ERK in carboplatin induced death of breast cancer cells. Curr Cancer Drug Targets 8: 741-752, 2008.
34. Singh S, Upadhyay AK, Ajay AK, et al: p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis. FEBS Lett 581: 289-295, 2007. (Pubitemid 46110832)
35. Wu J, Liu Q and Lee RJ: A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm 316: 148-153, 2006. (Pubitemid 43786219)
36. Gupta Y, Jain A, Jain P, et al: Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells. J Drug Target 15: 231-240, 2007. (Pubitemid 46562636)
37. Zhai G, Wu J, Xiang G, et al: Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. J Nanosci Nanotechnol 9: 2155-2161, 2009.
38. Lee RJ and Low PS: Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1233: 134-144, 1995.
39. Aronov O, Horowitz AT, Gabizon A, et al: Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjug Chem 14: 563-574, 2003. (Pubitemid 36597366)
40. Chiu GN, Edwards LA, Kapanen AI, et al: Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther 6: 844-855, 2007. (Pubitemid 46554554)